A genetic test for immunosuppressant dose selection?
Thummel
Kenneth E
KE
Department of Pharmaceutics, University of Washington, Seattle, Washington, USA. thummel@u.washington.edu
D015331:Cohort Studies; D016572:Cyclosporine / Q000008:administration & dosage / Q000493:pharmacokinetics*; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics*; D004305:Dose-Response Relationship, Drug; D018432:Drug Resistance, Multiple / Q000235:genetics; D005838:Genotype; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D016030:Kidney Transplantation / Q000276:immunology; D027425:ATP-Binding Cassette, Sub-Family C Proteins / Q000235:genetics*; D011110:Polymorphism, Genetic / Q000235:genetics*; D016559:Tacrolimus / Q000008:administration & dosage / Q000493:pharmacokinetics*
D016572:Cyclosporine; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System; D007166:Immunosuppressive Agents; D027425:ATP-Binding Cassette, Sub-Family C Proteins; D016559:Tacrolimus; C104464:CYP3A protein, human; C421109:multidrug resistance-associated protein 1